Bisphosphonates promote jaw osteonecrosis through facilitating bacterial colonisation

Bioscience Hypotheses

Volumn 2, Issue 1, 2009, Pages 34-36

  Kos, Marcin ^a   Luczak, K ^b  

^a KLINIKUM MINDEN   (Germany)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Bisphosphonates; Jaw osteonecrosis; Pamidronate; Zoledronate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; HYDROXYAPATITE; PAMIDRONIC ACID;

ACTINOMYCES; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ADHERENCE; BONE CANCER; BONE NECROSIS; BONE TURNOVER; DENTAL SURGERY; DRUG SAFETY; FIBROUS DYSPLASIA; GRAM POSITIVE BACTERIUM; HUMAN; HYPERCALCEMIA; HYPOTHESIS; INCIDENCE; JAW DISEASE; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; OSTEOMYELITIS; OSTEOPOROSIS; PAGET BONE DISEASE; PATHOGENESIS; RISK FACTOR; STAPHYLOCOCCUS AUREUS; THEORY;

BACTERIA (MICROORGANISMS); POSIBACTERIA;

EID: 58149194578     PISSN: 17562392     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bihy.2008.08.004     Document Type: Article

References (11)

1. Woo S.B., Hellstein J.W., and Kalmar J.R. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 (2006) 753-761
2. Sarin J., De Rossi S.S., and Akintoe S.O. Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis 14 (2008) 277-285
3. Gutta R., and Louis P.J. Bisphosphonates and osteonecrosis of the jaws: science and rationale. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104 (2007) 186-193
4. Marx R.E., Sawatari Y., Fortin M., and Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 63 (2005) 1567-1575
5. Ruggiero S.L., Mehrotra B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527-534
6. Marx R.E., Cillo Jr. J.E., and Ulloa J.J. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65 (2007) 2397-2410
7. Wang E.P., Kaban L.B., Strewler G.J., Raje N., and Troulis M.J. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 65 (2007) 1328-1331
8. Bertoldo F., Santini D., and Lo Cascio V. Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. Nat Clin Pract Oncol 4 (2007) 711-721
9. Little D.G., Smith N.C., Williams P.R., Briody J.N., Bilston L.E., Smith E.J., et al. Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis. J Bone Miner Res 18 (2003) 1300-1307
10. Pampu A.A., Dolanmaz D., Tuz H.H., and Karabacakoglu A. Experimental evaluation of the effects of zoledronic acid on regenerate bone formation and osteoporosis in mandibular distraction osteogenesis. J Oral Maxillofac Surg 64 (2006) 1232-1236
11. Ganguli A., Steward C., Butler S.L., Philips G.J., Meikle S.T., Lloyd A.W., et al. Bacterial adhesion to bisphosphonate coated hydroxyapatite. J Mater Sci Mater Med 16 (2005) 283-287